作者 | 哥吉拉 数据支持 | 勾股大数 据（www.gogudata.com） 三大指数集体回调，截止收盘，沪指跌 0.65% ，深证成指跌 1.76% ，创业板指跌 2.60% 。 沪深两市成交额超过 2.1 万亿，较昨日缩量逾 2000 亿。 日历效应正在演绎，临近节前，本周市场分歧加剧，成交量相对上周暗淡，但波动幅度却不断加大。 节假日海外市场走势、新关税、三季度末基金调仓等因素，为节后 A 股走势带来了不确定性。 这个时候，该避避风头了吗？ 科技股全线回调 01 金属铜概念股逆势走强，精艺股份三连板，江西铜业、铜陵有色跟涨。 消息面上，中国有色金属工业协会铜业分会表示坚决反对铜冶炼行业 "内卷式"竞争。同日全球第二大铜矿 - 印尼 格拉斯伯格矿区因泥石流事故宣布"不可抗力"而停产。作为全球第二大铜矿， Grasberg 矿山的突然停产立即引 发市场对供应中断的担忧。 风电股反复走强，吉鑫科技 2 连板，明阳智能、威力传动涨停，日月股份触及涨停。 | | | 风电概念股涨幅 | | | --- | --- | --- | --- | | 序号 | 代码 | 名称 | 涨跌幅 √ | | 1 | 300 ...

↑点击上面图片 加雪球核心交流群 午后跳水，三大指数震荡走跌，截至收盘， 沪指跌0.65% ， 深成指跌1.76% ， 创业板指跌2.60% 。 沪深两市成交额2.15万亿 ， 较上一个交易日缩量2242亿， 全市场超3400只个股下跌 。 板块方面 ， 风电 、 保险等板块涨幅居前 ， 游戏 、 算力硬件 、 光刻机等板块跌幅居前。 港股也走低，恒生指数跌超1%，恒生科技指数跌近3%，小米集团、金山云跌超7%等。 特朗普，突发重磅！ AI、半导体大跌 以AI为主线的科技股今天集体走弱，工业富联大跌5%，寒武纪跌超3%，立讯精密大跌超6%，瑞芯微、芯原股份、 领益智造、景旺电子等 跌超6 %。 9月26日午后，突然传来重磅消息。据路透社报道，消息人士称，特朗普政府正在考虑一项新的半导体政策，要求芯片公司在国内制造的半导体数 量与其客户从海外生产商进口的半导体数量相同，如果公司未能长期保持这种1:1的比例，将面临大约100%的关税。 美国商务部长霍华德·卢特尼克与半导体行业高管讨论了这一概念，理由是美国科技公司严重依赖海外芯片生产，容易受到多重因素影响，对经济 安全形成威胁。 知情人士表示，根据新制度，如果一家 ...

Group 1 - The article discusses the new tariffs announced by President Trump on various imported products, including a 25% tariff on heavy trucks, 50% on kitchen cabinets, 30% on furniture, and 100% on patented and branded drugs starting from October 1, 2025, unless companies build manufacturing plants in the U.S. [3][8][10] - The pharmaceutical sector in the Asia-Pacific market experienced a decline following the announcement, with the A-share pharmaceutical and biotechnology sector also showing a downward trend [4][6][10] - Specific indices related to weight-loss drugs, innovative drugs, and CROs saw significant declines, with the weight-loss drug index dropping by 1.56% and the innovative drug index by 1.48% [5][6] Group 2 - Individual stocks such as Sunflower and Aosaikang saw substantial declines, with Sunflower dropping over 12% and Aosaikang down by 9% [6][7] - The Hong Kong biotechnology index opened nearly 2% lower and continued to decline, with companies like MicroPort Medical and WuXi Biologics showing notable drops [7][10] - The article highlights that the high tariffs could increase costs and disrupt the drug supply chain, potentially putting patients at risk [9][10] Group 3 - The article mentions that major pharmaceutical companies like Johnson & Johnson and GlaxoSmithKline have announced plans to increase investments in the U.S. in response to the tariffs, with Johnson & Johnson planning to invest $55 billion [10] - The long-term implications of Trump's tariff policy could lead to higher drug costs for patients, as the high production costs in the U.S. may offset any benefits from the tariffs [10]

Group 1 - President Trump announced new tariffs on various imported products, effective October 1, including a 25% tariff on heavy trucks, 50% on kitchen cabinets and related materials, 30% on imported furniture, and 100% on patented and branded drugs [1] - The tariffs on drugs will only be waived if companies are building pharmaceutical factories in the U.S., with "building" defined as breaking ground or being under construction [1] - The pharmaceutical industry is warned that high tariffs may increase costs and disrupt drug supply chains, potentially putting patients at risk [7] Group 2 - The U.S. has a high dependency on imported drugs, with 70% of its pharmaceutical supply coming from abroad, prompting the administration to encourage domestic production through tariffs [7] - Major pharmaceutical companies like Johnson & Johnson, GlaxoSmithKline, and Eli Lilly have announced plans to increase investments in U.S. production, with Johnson & Johnson committing $55 billion [7] - The long-term implications of the tariff policy may lead to increased drug costs for patients, as domestic production costs in the U.S. are significantly higher than in other countries [7][8]

Group 1 - The pharmaceutical sector in both A-shares and Hong Kong stocks experienced a collective decline on September 26 [1] - In A-shares, Sunflower dropped by 10%, while Guangsheng Tang and Aosaikang fell over 8%. Other companies like Jimin Health, Hanyu Pharmaceutical, Wanbangde, Hengrui Medicine, and Huiyu Pharmaceutical also saw declines [1] - In Hong Kong stocks, WuXi AppTec decreased by over 5%, BeiGene fell by more than 4%, and Fosun Pharma dropped nearly 2% [1]

Core Viewpoint - The pharmaceutical sector in the Asia-Pacific market experienced a significant decline, with various indices showing notable drops, particularly in the weight loss drugs, innovative drugs, and CRO sectors [1][2]. Group 1: Market Performance - The A-share pharmaceutical and biotechnology sector saw a downturn, with weight loss drug index dropping by 1.56%, innovative drug index by 0.61%, and CRO index by 0.40% [2]. - Individual stocks such as Sunflower (向日葵) fell over 10%, while Aosaikang (奥赛康) and Guangshengtang (广生堂) also experienced significant declines of 9.02% and 6.56% respectively [3]. Group 2: Hong Kong and Japan Market Impact - The Hang Seng Biotechnology Index opened down nearly 2% and continued to decline, with companies like MicroPort Medical (微创医疗) and BeiGene (百济神州) showing notable drops of 5.47% and 4.75% respectively [4]. - In Japan, companies such as Sumitomo Pharma (住友制药) and Daiichi Sankyo (第一三共) also faced declines exceeding 4% and 3% respectively [4]. Group 3: External Factors - The recent announcement by U.S. President Trump regarding a new round of high tariffs on imported goods, including a punitive 100% tariff on patented and branded pharmaceuticals, is expected to impact the pharmaceutical industry significantly [5].

Core Viewpoint - The pharmaceutical sector in the Asia-Pacific market experienced a significant decline, particularly in China, with various indices related to weight-loss drugs, innovative drugs, and CROs showing notable drops [1][5]. Group 1: Market Performance - The A-share pharmaceutical and biotechnology sector saw a downturn, with the weight-loss drug index dropping by 1.56%, the innovative drug index by 1.48%, and the CRO index by 1.43% [2]. - Individual stocks such as Sunflower fell over 10%, while other companies like Aosaikang, Guangshengtang, and Jiming Health also reported significant declines [3]. Group 2: Stock Details - Specific stock performances included: - Sunflower (300111) at 7.90, down 12.22% [3] - Aosaikang (002755) at 21.18, down 9.02% [3] - Guangshengtang (300436) at 113.59, down 6.56% [3] - Jiming Health (603222) at 10.98, down 6.15% [3] - In the Hong Kong market, the Hang Seng Biotechnology Index opened nearly 2% lower, with companies like MicroPort Medical, CanSino Biologics, and BeiGene showing significant declines [4]. Group 3: External Factors - A major contributing factor to the decline was the announcement by U.S. President Trump regarding new tariffs, including a punitive 100% tariff on pharmaceutical products, effective October 1 [5].

Group 1 - The innovative drug sector experienced an initial adjustment, with several companies, including Aosaikang, hitting the daily limit down [1] - Other companies such as Guangshengtang, Jimin Health, Huilong Pharmaceutical-W, Saili Medical, Rongchang Bio, and Wanbangde also saw declines [1]

Core Viewpoint - The company is currently facing legal issues related to the forgery of company seals, but its new drug development projects are progressing as planned, and the management is focused on enhancing operational efficiency and market expansion [1] Group 1: Legal and Operational Updates - The police have preliminarily identified the facts regarding the case of forgery involving He Qinghong, who has been arrested by the Huangyan District Procuratorate, with further investigations ongoing [1] - The company assures that its operations are normal and all business segments are developing steadily [1] Group 2: Strategic Initiatives - The management plans to leverage the innovative policies of the Boao Lecheng Pilot Zone to strengthen external collaborations and increase investment in innovative drug research [1] - The company holds a 51% stake in Boao International Hospital, which is intended to be developed into a high-level clinical research center and translational medicine platform [1] Group 3: Future Focus - In the second half of the year, the management will concentrate on the development of existing business segments, enhance market expansion efforts, and optimize asset utilization to improve operational performance and create greater value for shareholders [1]

(编辑：林辰)关键字： 医药 下半年，公司管理层将进一步聚焦现有业务板块发展，加大市场拓展力度，盘活资产，提升经营业绩水 平，为股东创造更大价值。 （上证路演） 9月25日，济民健康举办2025年半年度业绩说明会。会上管理层回应，截至目前，公安机关已初步查明 "何清红等人伪造公司印章"案的基本事实，何清红已由黄岩区检察院批准逮捕，相关案件仍在进一步侦 查中。目前，公司的新药研发项目均按计划稳步推进中，如果新的进展，公司将依照规则进行披露。目 前公司经营正常，各板块稳健发展，公司管理层将努力提升经营管理水平。 此外，管理层还提到，公司将充分利用海南博鳌乐城先行区的创新政策，进一步加强对外合作，加大对 创新药的研发投入，将博鳌国际医院打造成为高水平的临床研究中心和转化医学平台。 公司目前持有博鳌国际医院51%的股权。其他49%的股份包括公司控股股东双鸽集团及其他自然人，涉 及多方利益。公司后续如有相关安排或进展，公司将及时披露相关信息。 ...